TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07157033: A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With L

Sponsor: Xerient Pharma · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 36 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,060,290

Rescue Site Savings

+$706,860

Unlock Full NCT07157033 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07157033 Rescue Dossier →